WuXi生物logics和Vertex制药公司作为三特T细胞自免疫疾病参与者的伙伴,Vertex公司获得全球权利,WuXi公司接受付款和发挥研发作用。 WuXi Biologics and Vertex Pharmaceuticals partner on a trispecific T-cell engager for autoimmune diseases, with Vertex gaining global rights and WuXi receiving payments and R&D roles.

WuXi生物logics和Vertex制药公司达成了一项协议,将针对B细胞自免疫疾病的临床前三联性T细胞使用者作为治疗对象。 WuXi Biologics and Vertex Pharmaceuticals have entered a deal for a preclinical trispecific T-cell Engager targeting B-cell autoimmune diseases. Vertex公司获得了开发分子和将其商业化的专属全球权利,而WuXi公司则收到预付付款以及潜在的里程碑和特许使用费付款。 Vertex gains exclusive global rights to develop and commercialize the molecule, while WuXi receives an upfront payment and potential milestone and royalty payments. WuXi还将利用其CRDMO能力,为下一代TCE提供研发服务。 WuXi will also provide R&D services for next-generation TCEs, leveraging its CRDMO capabilities. 合作凸显了WuXi在生物生物学发现和Vertex输油管扩张方面的领导地位。 The collaboration underscores WuXi’s leadership in biologics discovery and Vertex’s pipeline expansion.